Zydus Lifesci. Q1 FY27 Earnings Call — Analysis (NSE: ZYDUSLIFE)
Zydus Lifesciences reports strong Q1 FY27 with 22% YoY revenue growth, EBITDA margin of 24.1%, and US branded reaching 10%; management reiterates double-digit revenue growth and 24%+ margin guidance for FY27.
Result quality: watch — Margin pressure. Management sentiment: optimistic.
The take
Q1FY27 Consolidated Revenue ₹8,020 Cr ( +22% YoY ) . New guidance — FY27 india formulations revenue grow… mid-teens growth, outperforming market by 300-500 bps . New story: Branded portfolio transformation to two-thirds… .
Results
Revenue ₹8,020 Cr (+22% YoY); EBITDA ₹1,930 Cr, margin 24.1%; net profit ₹940 Cr; net debt/EBITDA 0.7x.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹8,020 Cr | +22% | yoy · Q1FY27 |
| EBITDA | ₹1,930 Cr | +na | none · Q1FY27 |
| EBITDA Margin | 24.1% | +na | point_in_time · Q1FY27 · Q1FY27 |
| Net Profit | ₹940 Cr | +na | none · Q1FY27 |
| Net Debt/EBITDA | 0.7x | +na | point_in_time · Q1FY27 · as on 30-Jun-2026 |
| India Formulations YoY Growth | 20% | +na | yoy · Q1FY27 · yoy growth |
| International Markets Formulations Revenue | ₹970 Cr | +34% | yoy · Q1FY27 |
| US Revenue | ₹3,100 Cr | +5% | qoq · Q1FY27 |
| Consumer Wellness Revenue | ₹1,430 Cr | +67% | yoy · Q1FY27 |
| Medical Devices Revenue | ₹280 Cr | +na | none · Q1FY27 |
| Branded Share of Total Revenue | over 55% | +na | point_in_time · Q1FY27 · of total revenue |
| US Branded Share of US Revenue | 10% | +na | point_in_time · Q1FY27 · of US revenue |
Guidance
FY27 revenue growth maintained as strong double-digit; EBITDA margin guidance maintained at 24%+; capex of ₹1,500–1,600 Cr guided.
What management committed to
- Zydus Lifesciences will deliver strong double-digit revenue growth for FY27. — strong double-digit, FY27
- Zydus Lifesciences EBITDA margin will be 24%+ in FY27. — 24%+, FY27
- India formulations business will grow mid-teens and outperform the market by at least 300-500 bps in FY27. — mid-teens growth, outperforming market by 300-500 bps, FY27
- US generics business will grow at around single-digit in FY27. — single-digit, FY27
- Capex for FY27 will be around ₹1,500-1,600 crores. — ₹1,500-₹1,600 crores, FY27
- The branded business share of total revenue will exceed two-thirds of overall revenue over the medium term. — exceed two-third of overall revenue, medium term
- EBITDA margin will improve to the 28-30% range as Zydus Lifesciences moves closer to the 5-year period (FY30). — 28-30%, FY30
- Assertio (Rolvedon) will contribute $15-20 million per quarter run rate. — $15-$20 million per quarter, FY27
- Saroglitazar will be launched in the US in FY28 (April launch). — FY28 launch, FY28
- Saroglitazar peak sales potential is conservatively $200-300 million, and optimistically $400+ million. — $200-$300 million conservative, $400+ million optimistic, peak
- Zydus Lifesciences will achieve vaccine revenue of ₹300-400 crore and is on track. — ₹300-400 crore, FY27
- Consumer Wellness business will grow double-digit in FY27. — double-digit, FY27
Key themes
Branded transformation and innovation-led scale-up
How the narrative shifted
- Branded portfolio transformation to two-thirds of revenue: Management positions the shift from generics to branded formulations as the central growth and margin lever, targeting branded share > 66% over medium term.
- US specialty build-out and biosimilars entry: The US branded business hitting 10% share, Assertio acquisition, and Saro priority review are framed as the start of a durable shift toward innovation-led US revenue.
- India market outperformance fueled by chronic and innovation: India formulations growing 20% and consistent market outperformance are attributed to chronic therapies, innovation portfolio, and biosimilars scaling up.
- International markets as a formidable growth pillar: Emerging markets and Europe (including UK) are delivering strong growth, with new geographies and first generic launches adding momentum.
- Capex cycle for capacity and new capabilities: High capex of ₹1,500-1,600 Cr is directed at SEZ-3, R&D, CAR-T, vaccines, and wellness land acquisition, laying groundwork for future growth.
- Pipeline catalysts: Saro, Desidustat, vaccines, biosimilars: FDA priority review for Saro, Phase III for Desidustat in sickle cell, and progress in ADC biosimilars and vaccines are highlighted as near-to-medium term value drivers.
- Margin management amid investment phase: Despite SG&A increase from acquisitions and Saro spend, management maintains 24%+ margin for FY27 and aims for 28-30% long-term as branded mix rises.
- Consumer wellness scaling with digital and analytics: Consumer wellness achieves 67% growth; investments in analytics and digital capabilities are positioned as enablers of sustainable profit growth.
Operational commentary
- India formulations grew 20% YoY, outperforming market; chronic portfolio share reached 54.2% (+360 bps over 4 years), driven by innovation and biosimilars
- US branded business now 10% of US revenue; launched Ranibizumab biosimilar and acquired Assertio Holdings (Rolvedon), expecting $15–20M quarterly run rate
- US generics: filed 5 ANDAs, received 9 approvals (4 tentative), launched 11 products; Indocyanine Green launched with 180-day CGT exclusivity
- International markets formulations grew 34% YoY to ₹970 Cr; Europe rebounded with strong growth in France, Spain, and UK, plus new market entries
- Consumer Wellness revenue ₹1,430 Cr (+67% YoY); Comfort Click like-to-like growth 25%; domestic skin & hair care +35%, food & nutrition +16%
- Saroglitazar NDA granted FDA priority review for PBC; launch preparation for FY28 underway; peak sales conservatively $200–300M, optimistic $400M+
- Desidustat received approval for Phase III in sickle cell disease in India with ICMR; China partner progressing towards reimbursement inclusion
- Second ADC biosimilar initiated Phase III trial in India; vaccines completed Phase II for bivalent typhoid conjugate vaccine, Phase I for chikungunya vaccine
- MR vaccine dossier submitted to WHO and accepted for review
- Injectable facility at Zydus Biotech Park received EIR with VAI classification; JV with Sunshine Healthcare for Sri Lanka manufacturing facility
- Capex ₹1,500–1,600 Cr guided for FY27, covering SEZ-3, R&D center, CAR-T facility, vaccines DS facility, and wellness land acquisition
Analyst Q&A
Q. Would Q1 strong growth lead to higher-than-guided FY27 growth?
We stay with the guidance of strong double-digit growth for the year; India mid-teens, US single-digit.
Q. What is driving the increase in operating costs and is the 24%+ margin guidance still intact?
Cost increase driven by acquisitions (Zylidac, Assertio) and freight; Saro costs will rise in 2H; margin guidance of 24% maintained.
Q. Can you break down the US branded 10% and what is the Assertio contribution?
Sentynl rare disease ~$60M; 505(b)(2) products the rest; Assertio to add from next quarter, taking branded share to ~15%.
Q. What is the gross margin dip reason and trajectory?
Mirabegron settlement cost impact; still a profitable product; 24% EBITDA margin guidance factors it in.
Q. What is the expected Saro launch cost and revenue build-up?
FY28 launch; first 2 years investment phase with no significant revenue in first year; we are guiding margins accordingly.
Research and educational content only. Not investment advice.